TABLE 2.
Identification of neutrophil protease cleavage products of proHD5 in urethral lavagesd
| Protease | HD5 peptidea | Cleavage siteb | Expected masse | Patient | Detected masse | Deviation (%) |
|---|---|---|---|---|---|---|
| EL, PR | 53-94 | S52*A53 | 4,610.27 | ND | ND | |
| EL, PR | 56-94 | R55*T56 | 4,269.8c | NGU2533 | 4,255 | 0.33 |
| CT2192 | 4,250 | 0.37 | ||||
| CT2309 | 4,254 | 0.35 | ||||
| GC2403 | 4,288 | 0.42 | ||||
| EL, PR | 57-94 | T56*S57 | 4,168.74 | N2361 | 4,136 | 0.77 |
| GC2414 | 4,150 | 0.43 | ||||
| EL | 62-94 | A61*R62 | 3,738.32c | GC2182 | 3,755 | 0.45 |
| GC2403 | 3,741 | 0.08 | ||||
| EL | 64-94 | A63*T64 | 3,511.05c | CT2192 | 3,517 | 0.17 |
| CT2309 | 3,517 | 0.17 | ||||
| GC2182 | 3,506 | 0.14 | ||||
| GC2403 | 3,518 | 0.19 | ||||
| GC2414 | 3,518 | 0.19 |
a
Peptides (aa) identified by N-terminal sequencing and/or MALDI analysis.
b
Amino acids and their positions flanking the cleavage site (*).
c
Masses also detected after in vitro cleavage of proHD5 with human neutrophil granule extract.
d
EL, elastase; PR, proteinase 3; ND, not detected; NGU, nongonococcal nonchlamydial urethritis; CT, chlamydial urethritis; GC, gonococcal urethritis; N, normal (healthy).
e
Masses (expected and detected) are reported in daltons.